Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma
The developed PTMLS system represents an effective instrument for individualized prognostic evaluation and immunotherapy stratification in both LUAD and diverse cancer populations. The identification of B4GALT2 as a previously unrecognized oncogenic factor involved in immune exclusion presents a novel therapeutic avenue for LUAD treatment and immunotherapy optimization.
Authors
- Dingli Wang (ORCID: https://orcid.org/0000-0002-7032-2342)
- Zhenfa Zhang (ORCID: https://orcid.org/0000-0002-9627-2590)
- Guangyao Zhou (ORCID: https://orcid.org/0000-0002-8966-4617)
- Shuai Jiang (ORCID: https://orcid.org/0000-0002-6722-176X)
- Ge Zhang (ORCID: https://orcid.org/0000-0002-3116-3246)
- Lianmin Zhang (ORCID: https://orcid.org/0000-0002-7419-9628)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Jiangsu Province Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-010787
- Citations
- 69
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 72.13
Funders
- Natural Science Foundation of Tianjin City